Article
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Antimicrobial agents and chemotherapy - 1 Mar 2000
Demeter L M, Shafer R W, Meehan P M, Holden-Wiltse J, Fischl M A, Freimuth W W, Para M F, Reichman R C
Abstract excerpt
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.